|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 58.82 EUR | +1.34% |
|
+0.17% | -7.24% |
| 05-13 | Spanish stocks - Factors to watch on May 13 | RE |
| 05-09 | Laboratorios Farmaceuticos Rovi, S.A., Q1 2026 Earnings Call, May 06, 2026 |
Sales 2025 by Business Segment
Sales 2025 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Pharmaceutical Products | ||||||||||
Manufacturing | 472M | 619M | 644M | 600M | 494M | |||||
Total Assets | 373M | 636M | 774M | 790M | 923M | |||||
Interest Expense | - | - | - | 1.22M | 697K | |||||
Income Tax Expense | 35.43M | 52.84M | 49.57M | 43.79M | 39.62M | |||||
CAPEX | -35.19M | -49.29M | -51.21M | -59.44M | -59.4M | |||||
EBT | 172M | 243M | 237M | 214M | 197M | |||||
EBITDA | 183M | 258M | 251M | 232M | 217M | |||||
D&A | 11.12M | 14.17M | 15.2M | 18.78M | 21.03M | |||||
Operating Income | 172M | 243M | 235M | 213M | 196M | |||||
Net Income | 136M | 190M | 187M | 170M | 157M | |||||
Other | - | - | - | - | 99K | |||||
Total Assets | 483K | 474K | 1.04M | 2.16M | 5.43M | |||||
Interest Expense | - | - | - | -26K | 307K | |||||
Income Tax Expense | -9K | -3K | -9K | -18K | -182K | |||||
CAPEX | - | - | - | - | -800K | |||||
EBT | -49K | -12K | -82K | -199K | -1.42M | |||||
EBITDA | -49K | -12K | -76K | -152K | -1.58M | |||||
D&A | - | - | - | 21K | 137K | |||||
Operating Income | -49K | -12K | -76K | -173K | -1.72M | |||||
Net Income | -40K | -9K | -73K | -181K | -1.23M | |||||
Pharmaceutical Product Distribution | ||||||||||
Marketing | 384M | 414M | 420M | 428M | 474M | |||||
Total Assets | 492M | 490M | 461M | 483M | 544M | |||||
Interest Expense | - | - | - | 60.63M | 23.4M | |||||
Income Tax Expense | -4.92M | 5.83M | -982K | 604K | 3.48M | |||||
CAPEX | -9.83M | -6.45M | -9.77M | -6.13M | -13.66M | |||||
EBT | 39.57M | 16.41M | -22.6M | 42.06M | 23.39M | |||||
EBITDA | 23.47M | 22.82M | -11.82M | -9.3M | 9.38M | |||||
D&A | 10.25M | 8.72M | 9.15M | 9.27M | 9.39M | |||||
Operating Income | 13.22M | 14.09M | -20.97M | -18.57M | -15K | |||||
Net Income | 44.49M | 10.58M | -21.62M | 41.46M | 19.91M | |||||
Inter-Segment Transactions | -207M | -216M | -235M | -264M | -225M | |||||
Total Assets | -123M | -229M | -410M | -411M | -434M | |||||
Interest Expense | - | - | - | -63.54M | -26.99M | |||||
Income Tax Expense | -949K | -365K | 1.53M | -3.56M | -20K | |||||
EBT | -28.45M | -1.44M | 6.11M | -78.31M | -35.44M | |||||
EBITDA | -3.77M | -1.46M | 5.72M | -14.82M | -8.64M | |||||
D&A | - | -22K | -18K | -49K | -184K | |||||
Operating Income | -3.77M | -1.44M | 5.73M | -14.77M | -8.45M | |||||
Net Income | -27.5M | -1.07M | 4.59M | -74.75M | -35.42M | |||||
Total Assets | -9.49M | -18.92M | -26.43M | -32.05M | -82.24M |
Geographical Revenue Distribution History
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Spain | 257M | 264M | 273M | 277M | 285M | |||||
Total Assets | 650M | 816M | 741M | 771M | 888M | |||||
OECD Countries | 244M | 377M | 381M | 305M | 242M | |||||
European Union | 120M | 137M | 144M | 146M | 174M | |||||
Total Assets | 3.8M | 2.39M | 5.66M | 7.84M | 6.67M | |||||
Total Assets | 2.04M | 6.2M | 5.44M | 4.69M | 6.14M | |||||
Total Assets | 30.7M | 16.92M | 15.54M | 18.4M | 17.8M | |||||
Total Assets | 34.31M | 31.28M | 27.28M | 23.52M | 30.48M | |||||
Total Assets | 10.94M | 5.23M | 4.74M | 6.3M | 6.22M | |||||
Total Assets | 542K | 378K | 278K | 168K | 5K | |||||
Total Assets | - | 262K | 229K | 202K | 167K | |||||
Total Assets | - | - | - | - | 669K | |||||
Other Countries | 28.79M | 40.12M | 31.63M | 35.87M | 42.25M | |||||
Total Assets | - | - | - | - | - |
- Stock Market
- Stocks
- ROVI Stock
- Financials Laboratorios Farmaceuticos Rovi, S.A.
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
